Emergent Biosolutions (EBS) Expected to Post Quarterly Earnings on Wednesday

Posted by Francis Steltz on Jul 29th, 2026

Emergent Biosolutions (NYSE:EBS – Get Free Report) will likely be announcing its Q2 2026 results after the market closes on Wednesday, August 5th. Analysts expect the company to post earnings of ($0.0850) per share and revenue of $177.50 million for the quarter. Individuals may visit the the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Wednesday, August 5, 2026 at 5:00 PM ET.

Emergent Biosolutions (NYSE:EBS – Get Free Report) last issued its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported $0.21 EPS for the quarter, topping the consensus estimate of ($0.25) by $0.46. The company had revenue of $156.10 million during the quarter, compared to analyst estimates of $145.00 million. Emergent Biosolutions had a negative net margin of 1.27% and a positive return on equity of 10.76%.

Emergent Biosolutions Stock Performance

NYSE:EBS opened at $7.32 on Wednesday. The company has a debt-to-equity ratio of 1.10, a quick ratio of 2.08 and a current ratio of 4.29. The stock has a market capitalization of $377.63 million, a PE ratio of -26.14 and a beta of 2.34. Emergent Biosolutions has a fifty-two week low of $5.61 and a fifty-two week high of $14.06. The company has a fifty day moving average of $8.13 and a two-hundred day moving average of $9.05.

Insider Activity

In other Emergent Biosolutions news, Director Kathryn C. Zoon sold 17,202 shares of the business’s stock in a transaction on Friday, May 1st. The stock was sold at an average price of $8.40, for a total transaction of $144,496.80. Following the transaction, the director owned 79,941 shares of the company’s stock, valued at approximately $671,504.40. The trade was a 17.71% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Paul Anthony Williams sold 3,000 shares of the firm’s stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $8.40, for a total value of $25,200.00. Following the completion of the sale, the senior vice president directly owned 159,098 shares of the company’s stock, valued at $1,336,423.20. This trade represents a 1.85% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 64,925 shares of company stock valued at $543,512 in the last 90 days. 6.00% of the stock is owned by insiders.

Hedge Funds Weigh In On Emergent Biosolutions

Institutional investors have recently bought and sold shares of the company. State of Wyoming grew its stake in shares of Emergent Biosolutions by 32.5% in the 2nd quarter. State of Wyoming now owns 41,315 shares of the biopharmaceutical company’s stock valued at $264,000 after buying an additional 10,127 shares during the period. Mariner LLC raised its position in shares of Emergent Biosolutions by 18.4% during the 4th quarter. Mariner LLC now owns 21,274 shares of the biopharmaceutical company’s stock valued at $262,000 after buying an additional 3,307 shares during the period. Stirlingshire Investments Inc. acquired a new position in Emergent Biosolutions in the fourth quarter valued at approximately $261,000. B. Riley Wealth Advisors Inc. purchased a new position in Emergent Biosolutions in the second quarter worth approximately $241,000. Finally, Virtus Advisers LLC acquired a new stake in Emergent Biosolutions during the fourth quarter worth $241,000. 78.40% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on EBS. UBS Group reissued a “buy” rating on shares of Emergent Biosolutions in a research note on Tuesday, June 2nd. Weiss Ratings lowered Emergent Biosolutions from a “sell (d)” rating to a “sell (d-)” rating in a research note on Monday, May 11th. Finally, Benchmark reissued a “buy” rating on shares of Emergent Biosolutions in a report on Tuesday, June 2nd. Three analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $12.00.

Get Our Latest Stock Report on Emergent Biosolutions

About Emergent Biosolutions

(Get Free Report)

Emergent BioSolutions is a global specialty biopharmaceutical company focused on developing, manufacturing and commercializing medical countermeasures and specialty products that address public health threats. The company’s portfolio includes vaccines, antibody therapies and critical care products designed to protect against biological, chemical and emerging infectious disease threats. Emergent has longstanding partnerships with government agencies, including the U.S. Department of Defense and the Biomedical Advanced Research and Development Authority (BARDA), to support national preparedness programs.

Key commercial products in Emergent’s lineup include BioThrax (anthrax vaccine adsorbed), ACAM2000 (smallpox vaccine) and Vaxchora (cholera vaccine), alongside therapeutic treatments such as Anthrasil (anthrax immune globulin) and the naloxone-based nasal spray Narcan for opioid overdose reversal.

Earnings History for Emergent Biosolutions (NYSE:EBS)

Receive News & Ratings for Emergent Biosolutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions and related companies with MarketBeat.com's FREE daily email newsletter.